THE UK Medicines and
Healthcare products Regulatory
Agency has issued an update on
the use of rosiglitazone (Avandia),
with health professionals reminded
to “closely observe the current
contraindications and monitoring
requirements” for the drug, and “to
consider alternative treatments
where appropriate”.
A Europe-wide review of Avandia
was initiated in Jul after data
indicating increased cardiovascular
risk associated with the drug, and is
anticipated to reach its conclusion
after a meeting later this month.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Sep 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Sep 10
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.